NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $12.44 +0.73 (+6.23%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$12.40 -0.04 (-0.28%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nurix Therapeutics Stock (NASDAQ:NRIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$11.46▼$12.9050-Day Range$9.30▼$12.7952-Week Range$8.18▼$29.56Volume779,716 shsAverage Volume832,736 shsMarket Capitalization$948.43 millionP/E RatioN/ADividend YieldN/APrice Target$30.18Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreNRIX MarketRank™: Nurix Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 847th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.45% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 2.48%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.45% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 2.48%, indicating that investor sentiment is decreasing. News and Social Media2.2 / 5News Sentiment0.91 News SentimentNurix Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.Search Interest6 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,096.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Nurix Therapeutics is held by insiders.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Stock News HeadlinesNurix Therapeutics (NRIX) to Release Earnings on Thursday3 hours ago | americanbankingnews.comNurix Therapeutics, Inc. (NRIX) - Yahoo FinanceJune 28, 2025 | finance.yahoo.comTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift all boats equally. They're wrong. One project stands to benefit more than any other – not by accident, but seemingly by design. | Crypto 101 Media (Ad)NRIX Nurix Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comAnalysts Conflicted on These Healthcare Names: Align Tech (ALGN), Nurix Therapeutics (NRIX) and Thermo Fisher (TMO)June 18, 2025 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Telix Pharmaceuticals (OtherTLPPF)June 14, 2025 | theglobeandmail.comNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | globenewswire.comNurix drops after new early-stage trial data for lead assetJune 13, 2025 | msn.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.84 at the beginning of 2025. Since then, NRIX stock has decreased by 34.0% and is now trading at $12.44. View the best growth stocks for 2025 here. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its earnings results on Tuesday, April, 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. The firm had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative trailing twelve-month return on equity of 47.49% and a negative net margin of 369.40%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V). Company Calendar Last Earnings4/08/2025Today7/02/2025Next Earnings (Estimated)7/10/2025Fiscal Year End11/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$30.18 High Stock Price Target$41.00 Low Stock Price Target$16.00 Potential Upside/Downside+142.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$193.57 million Net Margins-369.40% Pretax Margin-369.08% Return on Equity-47.49% Return on Assets-36.10% Debt Debt-to-Equity RatioN/A Current Ratio6.26 Quick Ratio6.26 Sales & Book Value Annual Sales$54.55 million Price / Sales17.39 Cash FlowN/A Price / Cash FlowN/A Book Value$7.44 per share Price / Book1.67Miscellaneous Outstanding Shares76,240,000Free Float70,595,000Market Cap$948.43 million OptionableOptionable Beta2.15 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:NRIX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.